This financing round follows Hasten’s acquisition of the Chinese mainland exclusive rights for five cardiovascular and metabolism drugs from Takeda Pharmaceutical in March 2022. The company is focused on the development of an innovative late-stage business development pipeline. This will help create syn...
This financing round follows Hasten’s acquisition of the Chinese mainland exclusive rights for five cardiovascular and metabolism drugs from Takeda Pharmaceutical in March 2022. The company is focused on the development of an innovative late-stage business development pipeline. This will help create syn...
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK), on Monday, said it entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) for US$322 million. The portfolio to be divested to Hasten inc...